Skip to main content
. 2020 Dec 6;137(7):969–976. doi: 10.1182/blood.2020006052

Figure 2.

Figure 2.

One-way sensitivity analyses of TITAN trial with model parameters varied across ranges as shown. (A) Utility of well state. (B) Utility of disease state. (C) Cost of SOC arm. (D) Cost of caplacizumab. Purple dashed line represents baseline estimate.